Symptom treatment in the last days of life of geriatric patients
Conditions
Brief summary
Morphine and midazolam doses, time of administration and route of administration, Symptom control: discomfort scale, agitation/sedation scale and dyspnea scale, Adverse reactions: : nausea, vomiting, hallucinations, constipation, myoclonus, pruritus, hiccups, respiratory rate and other adverse reactions occurring that are related to the Morphine and Midazolam injection according to the nurse or doctor.
Detailed description
Morphine, morphine-3-glucuronide and morphine-6-glucuronide plasma concentrations, Midazolam and alpha-hydroxy-midazolam glucuronide plasma concentrations, Blood creatinine, urea, albumin, bilirubin, GGT, ALT, sodium, CRP and urinary creatinine concentrations
Interventions
DRUGMORPHINE
DRUGMIDAZOLAM
Sponsors
UZ Leuven
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Morphine and midazolam doses, time of administration and route of administration, Symptom control: discomfort scale, agitation/sedation scale and dyspnea scale, Adverse reactions: : nausea, vomiting, hallucinations, constipation, myoclonus, pruritus, hiccups, respiratory rate and other adverse reactions occurring that are related to the Morphine and Midazolam injection according to the nurse or doctor. | — |
Secondary
| Measure | Time frame |
|---|---|
| Morphine, morphine-3-glucuronide and morphine-6-glucuronide plasma concentrations, Midazolam and alpha-hydroxy-midazolam glucuronide plasma concentrations, Blood creatinine, urea, albumin, bilirubin, GGT, ALT, sodium, CRP and urinary creatinine concentrations | — |
Countries
Belgium
Outcome results
None listed